These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 29512200

  • 1. Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials.
    Gottlieb AB, Gordon K, Hsu S, Elewski B, Eichenfield LF, Kircik L, Rastogi S, Pillai R, Israel R.
    J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1305-1313. PubMed ID: 29512200
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials.
    McMichael A, Desai SR, Qureshi A, Rastogi S, Alexis AF.
    Am J Clin Dermatol; 2019 Apr; 20(2):267-276. PubMed ID: 30471012
    [Abstract] [Full Text] [Related]

  • 3. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
    Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, Papp K, Spelman L, Toth D, Kerdel F, Armstrong AW, Stingl G, Kimball AB, Bachelez H, Wu JJ, Crowley J, Langley RG, Blicharski T, Paul C, Lacour JP, Tyring S, Kircik L, Chimenti S, Callis Duffin K, Bagel J, Koo J, Aras G, Li J, Song W, Milmont CE, Shi Y, Erondu N, Klekotka P, Kotzin B, Nirula A.
    N Engl J Med; 2015 Oct; 373(14):1318-28. PubMed ID: 26422722
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
    Papp KA, Gordon KB, Langley RG, Lebwohl MG, Gottlieb AB, Rastogi S, Pillai R, Israel RJ.
    Br J Dermatol; 2018 Aug; 179(2):320-328. PubMed ID: 29488226
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials.
    Langley RG, Armstrong AW, Lebwohl MG, Blauvelt A, Hsu S, Tyring S, Rastogi S, Pillai R, Israel R.
    Br J Dermatol; 2019 Feb; 180(2):306-314. PubMed ID: 30328108
    [Abstract] [Full Text] [Related]

  • 7. Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial.
    Puig L, Lebwohl M, Bachelez H, Sobell J, Jacobson AA.
    J Am Acad Dermatol; 2020 Feb; 82(2):352-359. PubMed ID: 31175909
    [Abstract] [Full Text] [Related]

  • 8. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.
    Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, Toth D, Langley RG, Cather J, Gottlieb AB, Thaçi D, Krueger JG, Russell CB, Milmont CE, Li J, Klekotka PA, Kricorian G, Nirula A.
    Br J Dermatol; 2016 Aug; 175(2):273-86. PubMed ID: 26914406
    [Abstract] [Full Text] [Related]

  • 9. Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials.
    Hsu S, Green LJ, Lebwohl MG, Wu JJ, Blauvelt A, Jacobson AA.
    Br J Dermatol; 2020 Apr; 182(4):880-888. PubMed ID: 31276189
    [Abstract] [Full Text] [Related]

  • 10. Brodalumab: A Review in Moderate to Severe Plaque Psoriasis.
    Blair HA.
    Drugs; 2018 Mar; 78(4):495-504. PubMed ID: 29516365
    [Abstract] [Full Text] [Related]

  • 11. Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials.
    Kimball AB, Luger T, Gottlieb A, Puig L, Kaufmann R, Nikaï E, Zhu B, Edson-Heredia E, Carlier H, Lin CY, Goldblum O, Yosipovitch G.
    J Am Acad Dermatol; 2016 Dec; 75(6):1156-1161. PubMed ID: 27692498
    [Abstract] [Full Text] [Related]

  • 12. Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis.
    Kokolakis G, Vadstrup K, Hansen JB, Carrascosa JM.
    Dermatology; 2022 Dec; 238(4):620-629. PubMed ID: 34823247
    [Abstract] [Full Text] [Related]

  • 13. Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis.
    Viswanathan HN, Mutebi A, Milmont CE, Gordon K, Wilson H, Zhang H, Klekotka PA, Revicki DA, Augustin M, Kricorian G, Nirula A, Strober B.
    Value Health; 2017 Sep; 20(8):1174-1179. PubMed ID: 28964451
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials.
    Elewski B, Rich P, Lain E, Soung J, Lewitt GM, Jacobson A.
    J Dermatolog Treat; 2022 Feb; 33(1):261-265. PubMed ID: 32250714
    [Abstract] [Full Text] [Related]

  • 15. The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis.
    Sawyer L, Fotheringham I, Wright E, Yasmeen N, Gibbons C, Holmen Møller A.
    J Dermatolog Treat; 2018 Sep; 29(6):557-568. PubMed ID: 29323542
    [Abstract] [Full Text] [Related]

  • 16. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
    Blauvelt A, Reich K, Tsai TF, Tyring S, Vanaclocha F, Kingo K, Ziv M, Pinter A, Vender R, Hugot S, You R, Milutinovic M, Thaçi D.
    J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
    [Abstract] [Full Text] [Related]

  • 17. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI, Hooft L.
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [Abstract] [Full Text] [Related]

  • 18. Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.
    Augustin M, Lambert J, Zema C, Thompson EHZ, Yang M, Wu EQ, Garcia-Horton V, Geng Z, Valdes JM, Joshi A, Gordon KB.
    JAMA Dermatol; 2020 Dec 01; 156(12):1344-1353. PubMed ID: 33052382
    [Abstract] [Full Text] [Related]

  • 19. Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial.
    Papp KA, Blauvelt A, Kimball AB, Han C, Randazzo B, Wasfi Y, Shen YK, Li S, Griffiths CEM.
    J Eur Acad Dermatol Venereol; 2018 Sep 01; 32(9):1515-1522. PubMed ID: 29512196
    [Abstract] [Full Text] [Related]

  • 20. Malignancy Rates in Brodalumab Clinical Studies for Psoriasis.
    Gottlieb A, Lebwohl M, Liu C, Israel RJ, Jacobson A.
    Am J Clin Dermatol; 2020 Jun 01; 21(3):421-430. PubMed ID: 32207067
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.